Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for CytomX Therapeutics (CTMX) over the last 6 years, with Dec 2024 value amounting to $0.38.

  • CytomX Therapeutics' EPS (Weighted Average and Diluted) fell 228.57% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.48, marking a year-over-year increase of 182.35%. This contributed to the annual value of $0.38 for FY2024, which is 3900.00% up from last year.
  • As of FY2024, CytomX Therapeutics' EPS (Weighted Average and Diluted) stood at $0.38, which was up 3,900.00% from -$0.01 recorded in FY2023.
  • CytomX Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $0.38 for FY2024, and its period low was -$1.81 during FY2021.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$0.38, with a median of -$0.01 in 2023.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first decreased by 29.29% in 2021, then soared by 3,900.00% in 2024.
  • Yearly analysis of 5 years shows CytomX Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.40 in 2020, then declined by 29.29% to -$1.81 in 2021, then increased by 16.57% to -$1.51 in 2022, then surged by 99.34% to -$0.01 in 2023, then skyrocketed by 3,900.00% to $0.38 in 2024.